Should I buy or sell Processa Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Processa Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PCSA shares. View PCSA analyst ratings or view top-rated stocks .

How have PCSA shares performed in 2024?

Processa Pharmaceuticals' stock was trading at $6.6920 at the beginning of the year. Since then, PCSA stock has decreased by 77.4% and is now trading at $1.5150. View the best growth stocks for 2024 here .

When is Processa Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our PCSA earnings forecast .

How were Processa Pharmaceuticals' earnings last quarter?

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) issued its earnings results on Friday, November, 12th. The company reported ($3.80) earnings per share for the quarter, missing the consensus estimate of ($3.60) by $0.20. During the same quarter in the previous year, the company earned ($11.00) EPS.

When did Processa Pharmaceuticals' stock split?

Processa Pharmaceuticals shares reverse split on Monday, January 22nd 2024. The 1-20 reverse split was announced on Monday, January 22nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Processa Pharmaceuticals?

Shares of PCSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PCSA

Processa Pharmaceuticals (PCSA) Stock Price, News & Analysis

→ Biden out June 13; Kamala won’t replace him? (From Paradigm Press) (Ad)

Free PCSA Stock Alerts

$1.52

-0.16 (-9.55%)

(As of 04/15/2024 ET)

Compare

Today's Range: $1.50
▼
$1.65
50-Day Range: $1.52
▼
$2.99
52-Week Range: $1.45
▼
$18.00

Volume: 131,549 shs
Average Volume: 1.45 million shs
Market Capitalization: $4.33 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Processa Pharmaceuticals alerts:

Processa Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
1.56% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.13
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$105,895 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.19 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Processa Pharmaceuticals.

5.0

Short Interest

Percentage of Shares Shorted
1.56% of the float of Processa Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Processa Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Processa Pharmaceuticals has recently decreased by 11.17%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Processa Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Processa Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PCSA.

4.0

News and Social Media Coverage

News Sentiment
Processa Pharmaceuticals has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Processa Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
11 people have searched for PCSA on MarketBeat in the last 30 days. This is an increase of 175% compared to the previous 30 days.
MarketBeat Follows
3 people have added Processa Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Processa Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $105,895.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
22.20% of the stock of Processa Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
91.93% of the stock of Processa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Processa Pharmaceuticals is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Processa Pharmaceuticals is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Processa Pharmaceuticals has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

Trump’s “Tax Free” Retirement Strategy

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

Protect your retirement savings from the inevitable devaluation of the dollar…

About Processa Pharmaceuticals Stock (NASDAQ:PCSA)

Processa Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. Its pipeline includes three Chemotherapy drugs, including Capecitabine, PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; Gemcitabine, PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers; and Irinotecan, PCS11T to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. Processa Pharmaceuticals, Inc. was incorporated in 2011 and is based in Hanover, Maryland.

PCSA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PCSA Stock News Headlines

April 11, 2024 | msn.com

U.S. shares lower at close of trade; Dow Jones Industrial Average down 1.09%

April 11, 2024 | finance.yahoo.com

Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

April 7, 2024 | finance.yahoo.com

Insider Buyers At Processa Pharmaceuticals Recover Some Losses, But Still Down US$40k

April 5, 2024 | americanbankingnews.com

Processa Pharmaceuticals (NASDAQ:PCSA) Stock Price Down 1.7%

March 28, 2024 | nz.finance.yahoo.com

Eva Mendes says she had 'non-verbal agreement' with Ryan Gosling to be a stay-at-home mom

March 28, 2024 | globenewswire.com

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

March 25, 2024 | globenewswire.com

Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

February 24, 2024 | msn.com

Processa Pharmaceuticals (PCSA) Price Target Increased by 1900.00% to 81.60

February 21, 2024 | finance.yahoo.com

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

February 21, 2024 | globenewswire.com

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

February 14, 2024 | finance.yahoo.com

Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

February 14, 2024 | globenewswire.com

Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

February 6, 2024 | markets.businessinsider.com

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

February 6, 2024 | investing.com

Processa Pharmaceuticals Inc (PCSA)

February 1, 2024 | finance.yahoo.com

Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering

February 1, 2024 | msn.com

Processa Pharmaceuticals Announces Offering Pricing Details

January 27, 2024 | marketwatch.com

Processa Pharmaceuticals Shares Drop 24% After Pricing Offering

January 26, 2024 | msn.com

Processa Pharmaceuticals prices discounted stock and warrants offering to raise $7M

January 26, 2024 | msn.com

What's Going On With Anti Cancer Focused Processa Pharmaceuticals Stock Today?

January 26, 2024 | finance.yahoo.com

Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

January 25, 2024 | marketwatch.com

Processa Pharmaceuticals Shares More Than Double After Completing Safety Evaluation of Cancer Treatment

January 25, 2024 | finance.yahoo.com

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

January 20, 2024 | msn.com

Processa Pharmaceuticals Expands NGC-Cap Cancer Program

January 19, 2024 | finanznachrichten.de

Processa Pharmaceuticals, Inc.: Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

January 19, 2024 | msn.com

Why Processa Pharmaceuticals (PCSA) Stock Is Skyrocketing

See More Headlines

Receive PCSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Processa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/12/2021
Today: 4/15/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PCSA
CUSIP: N/A
CIK: 1533743
Web: www.processapharmaceuticals.com
Phone: (443) 776-3133
Fax: 443-288-4420
Employees: 15
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($7.44)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-11,120,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -141.42%
Return on Assets: -122.25%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.70
Quick Ratio: 7.70

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.05 per share
Price / Book: 0.37

Miscellaneous

Outstanding Shares: 2,860,000
Free Float: 2,222,000
Market Cap: $4.33 million
Optionable: Not Optionable
Beta: 0.53

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. George K. Ng Esq. (Age 50)
J.D., CEO & Director
Comp: $400.27k
Dr. David Young Ph.D. (Age 71)
Pharm.D., Co-Founder, President of Research and Development & Director
Comp: $160.2k
Dr. Sian E. Bigora Ph.D. (Age 64)
Pharm.D., Co-Founder and Chief Development & Regulatory Officer
Comp: $184.87k
Mr. James H. Stanker (Age 66)
Chief Financial Officer
Comp: $160.2k
Mr. Patrick Lin (Age 59)
Co-Founder, Chief Business & Strategy Officer
Comp: $117.15k
Ms. Wendy J. Guy (Age 60)
Co-Founder, Chief Administrative Officer & Corporate Secretary
Comp: $94.19k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PCSA Stock Analysis - Frequently Asked Questions

Should I buy or sell Processa Pharmaceuticals stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Processa Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PCSA shares.
View PCSA analyst ratings or view top-rated stocks.
How have PCSA shares performed in 2024?: Processa Pharmaceuticals' stock was trading at $6.6920 at the beginning of the year. Since then, PCSA stock has decreased by 77.4% and is now trading at $1.5150.
View the best growth stocks for 2024 here.
When is Processa Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our PCSA earnings forecast.
How were Processa Pharmaceuticals' earnings last quarter?: Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) issued its earnings results on Friday, November, 12th. The company reported ($3.80) earnings per share for the quarter, missing the consensus estimate of ($3.60) by $0.20. During the same quarter in the previous year, the company earned ($11.00) EPS.

When did Processa Pharmaceuticals' stock split?: Processa Pharmaceuticals shares reverse split on Monday, January 22nd 2024. The 1-20 reverse split was announced on Monday, January 22nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
How do I buy shares of Processa Pharmaceuticals?: Shares of PCSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PCSA) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial